Concordance of acquired mutations between metastatic lesions and liquid biopsy in metastatic colorectal cancer.
Concordance of acquired mutations between metastatic lesions and liquid biopsy in metastatic colorectal cancer.
复制标题
DOI：
10.2144/fsoa-2021-0059
复制
发表时间：
2021-12
影响因子：
2.5
通讯作者：
Nagasaka T
中科院分区：
文献类型：
--
作者：
Taniguchi F;Nyuya A;Toshima T;Yasui K;Mori Y;Okawaki M;Kishimoto H;Umeda Y;Fujiwara T;Tanioka H;Yamaguchi Y;Goel A;Nagasaka T
目的：评价聚合酶链式反应反向序列特异性寡核苷酸能否检测液体活检与获得性耐药转移灶之间的一致性。我们检测了四名接受抗表皮生长因子受体抗体治疗的RAS野生型转移性结直肠癌患者的化疗耐药灶和血液中的获得性突变。在一名患者中，转移灶在所有七种转移瘤中都含有不同的KRAS获得性突变；在患者获得耐药性后收集的血液中可以检测到两种获得性突变。除1例在原发肿瘤和腹膜扩散中证实有BRAF突变外，其他患者均未出现液体活检突变。基于PCR反向序列特异性寡核苷酸的液体活检是一种成功的方法，可以利用RAS突变谱的准确信息来捕获获得性突变。
To evaluate whether PCR-reverse sequence-specific oligonucleotide can examine the concordance between liquid biopsy and metastatic lesions with acquired resistance. We examined acquired mutations in chemoresistant lesions and blood obtained from four patients with RAS wild-type metastatic colorectal cancer who underwent treatment with anti-epidermal growth factor receptor antibodies. In one patient, metastatic lesions harbored diverse acquired mutations in KRAS in all seven metastases; the two acquired mutations were detectable in blood collected after the patient acquired resistance. None of the other patients exhibited liquid biopsy mutations, except one, with a BRAF mutation confirmed in primary tumor and peritoneal dissemination. Liquid biopsy based on PCR-reverse sequence-specific oligonucleotide is a successful procedure for capturing acquired mutations with precise information on the RAS mutational spectrum.